ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Sells $1,534,125.00 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Glenn Baity sold 37,500 shares of the business’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $40.91, for a total value of $1,534,125.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Glenn Baity also recently made the following trade(s):

  • On Wednesday, August 30th, Glenn Baity sold 26,507 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $34.87, for a total value of $924,299.09.
  • On Wednesday, August 9th, Glenn Baity sold 14,322 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $34.88, for a total value of $499,551.36.
  • On Thursday, July 20th, Glenn Baity sold 38,097 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $30.00, for a total value of $1,142,910.00.

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ ACAD) opened at 36.10 on Tuesday. ACADIA Pharmaceuticals Inc. has a 52-week low of $20.68 and a 52-week high of $41.20. The firm’s 50-day moving average price is $36.78 and its 200-day moving average price is $31.67. The firm’s market capitalization is $4.42 billion.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.17. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. The company had revenue of $30.50 million during the quarter, compared to the consensus estimate of $20.02 million. During the same period in the previous year, the firm posted ($0.63) earnings per share. ACADIA Pharmaceuticals’s quarterly revenue was up 30400.0% compared to the same quarter last year. On average, equities analysts predict that ACADIA Pharmaceuticals Inc. will post ($2.55) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Sells $1,534,125.00 in Stock” was published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/glenn-baity-sells-37500-shares-of-acadia-pharmaceuticals-inc-acad-stock/1697623.html.

Hedge funds have recently modified their holdings of the business. Envestnet Asset Management Inc. boosted its stake in ACADIA Pharmaceuticals by 23.0% in the first quarter. Envestnet Asset Management Inc. now owns 3,296 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 617 shares during the period. San Francisco Sentry Investment Group CA acquired a new position in ACADIA Pharmaceuticals in the second quarter valued at approximately $125,000. Oppenheimer Asset Management Inc. boosted its stake in ACADIA Pharmaceuticals by 10.0% in the second quarter. Oppenheimer Asset Management Inc. now owns 5,133 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 468 shares during the period. PNC Financial Services Group Inc. boosted its stake in ACADIA Pharmaceuticals by 138.8% in the first quarter. PNC Financial Services Group Inc. now owns 4,384 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 2,548 shares during the period. Finally, Flagship Harbor Advisors LLC acquired a new position in ACADIA Pharmaceuticals in the first quarter valued at approximately $202,000. Institutional investors own 97.10% of the company’s stock.

Several equities research analysts have weighed in on the company. ValuEngine upgraded ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, August 10th. Zacks Investment Research downgraded ACADIA Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Monday, July 17th. BidaskClub upgraded ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Leerink Swann restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Monday, October 9th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, October 5th. Seven analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $46.21.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.